Bridgeway Capital Management’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Bridgeway Capital Management’s Portfolio CMPI Stock Details CMPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-106,500	Closed	-$340K	–	1412
2022 Q1	$340K	Hold	106,500	–	–	0.01%	1040
2021 Q4	$306K	Hold	106,500	–	–	0.01%	1099
2021 Q3	$423K	Buy	106,500 +85,000	+395%	+$437K	0.01%	1080
2021 Q2	$128K	Sell	21,500 -50,015	-70%	-$354K	﹤0.01%	1300
2021 Q1	$868K	Buy	+71,515	New	+$1.02M	0.02%	913

Bridgeway Capital Management's CMPI Position: Q2 2022 in Review

Bridgeway Capital Management sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2022, closing a stake of 106,500 shares — an estimated $340K sold.

Bridgeway Capital Management first reported a position in CMPI in Q1 2021 and held it in 5 quarters. The position peaked at $868K in Q1 2021. 0 funds tracked by Wall St. Rank hold CMPI as of Q2 2022.

Bridgeway Capital Management reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Bridgeway Capital Management sold 106,500 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $340K.
Bridgeway Capital Management first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Bridgeway Capital Management's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $868K in Q1 2021.
0 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Bridgeway Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.